Miniaturized microelectronic devices for cost-effective point-of-care diagnostics

基因组学和蛋白质组学领域导致了疾病分子指纹的发现。这些突破为早期发现和治疗这些疾病提供了可能性，提高了加拿大和世界各地的医疗保健质量。有一个关键的缺失：获取每个患者分子指纹的技术。今天，这些技术-被称为分子诊断-是昂贵的，只能在集中的临床实验室运行。它们也容易出现假阳性。在这项提案中，我们将推进一项创新技术--一项基于小型化、低成本微芯片的技术--这将使我们能够更早、更便宜、更迅速地检测卵巢癌。我们将与Kalgene Pharmaceuticals密切合作。Kalgene正在商业化卵巢癌测试，将在医生办公室对所有绝经后妇女进行测试。他们迫切需要一种合适的设备，用于未加工样品中的蛋白质和核酸分析。由于UofT研究人员和Kalgene科学家之间的这一战略项目赠款合作，

The fields of genomics and proteomics have led to the discovery of molecular fingerprints of diseases. These breakthroughs offer the potential to detect and treat these diseases early, improving the quality of healthcare in Canada and around the world. There is one key missing piece: the technologies to take each patient's molecular fingerprint. Today, these technologies - known as molecular diagnostics - are costly, and can only be run in a centralized clinical lab. They are also prone to false positives. In this proposal, we will advance an innovative technology - one based on miniaturized, low-cost microchips - that will allow us to detect ovarian cancer earlier, more cheaply, and more rapidly. We will partner closely with Kalgene Pharmaceuticals. Kalgene is commercializing a test for ovarian cancer that will be performed in doctors' offices on all post-menopausal women. They urgently require a suitable device for both protein and nucleic acids analysis in unprocessed samples. As a result of this strategic project grant collaboration between researchers at UofT and scientists at Kalgene,